Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID) Clinical Trial

Official title:

A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01412385
• Other study ID #: 170903
• Secondary ID: 2010-019459-23
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: June 20, 2011
• Est. completion date: May 13, 2014

Study information

• Verified date: April 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to develop a 20% subcutaneous immunoglobulin treatment option for patients with primary immunodeficiency (PID) diseases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: May 13, 2014
• Est. primary completion date: May 13, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Subject must have a documented diagnosis of a form of primary humoral immunodeficiency involving antibody formation and requiring gammaglobulin replacement, as defined according to the IUIS Scientific Committee 2009, and by diagnostic criteria according to Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Clin Immunol 1999; 93:190-197. The diagnosis must be confirmed by the Medical Director prior to enrollment.

• Subject is 2 years or older at the time of screening

• Written informed consent is obtained from either the subject or the subject's legally authorized representative prior to any study-related procedures and study product administration

• Subject has been receiving a consistent dose of IgG over a period of at least 3 months prior to screening at an average minimum dose over that interval equivalent to 300 mg/kg body weight (BW)/4 weeks and a maximum dose equivalent to 1.0 gram/kg BW/4 weeks at a dosing frequency as follows:

1. intravenously (IV) at mean intervals of approximately 3 or 4 weeks or

2. subcutaneously (SC) at mean intervals of approximately 1 or 2 weeks

• Subject has a serum trough level of IgG > 5 g/L at screening

• Subject has not had a serious bacterial infection within the 3 months prior to screening

• Subject is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

• Subject has a known history of or is positive at screening for one or more of the following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for hepatitis C virus (HCV), PCR for human immunodeficiency virus (HIV) Type 1/2

• Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):

1. Persistent alanine aminotransferase (ALT) and aspartate amino transferase (AST) > 2.5 times the upper limit of normal for the testing laboratory

2. Persistent severe neutropenia (defined as an absolute neutrophil count [ANC] <= 500 /mm3)

• Subject has creatinine clearance (CLcr) value that is < 60% of normal for age and gender

• Subject has been diagnosed with or has a malignancy (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix), unless the disease-free period prior to screening exceeds 5 years

• Subject is receiving anti-coagulation therapy or has a history of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within 12 months prior to screening or a history of thrombophilia

• Subject has abnormal protein loss (protein losing enteropathy, nephrotic syndrome)

• Subject has anemia that would preclude phlebotomy for laboratory studies according to standard practice at the site

• Subject has an ongoing history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IV immunoglobulin, SC immunoglobulin, and/or Immune Serum Globulin (ISG) infusions

• Subject has immunoglobulin A (IgA) deficiency (IgA less than 0.07g/L) and known anti IgA antibodies

• Subject is on preventative (prophylactic) systemic antibacterial antibiotics at doses sufficient to treat or prevent bacterial infections, and cannot stop these antibiotics at the time of screening

• Subject has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening

• Subject has a bleeding disorder or a platelet count less than 20,000/µL, or who, in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of subcutaneous therapy

• Subject has total protein >9 g/dL or myeloma, or macroglobulinemia (IgM) or paraproteinemia

• Women of childbearing potential meeting any one of the following criteria

1. subject presents with a positive pregnancy test

2. subject is breast feeding

3. subject intends to begin nursing during the course of the study

4. subject does not agree to employ adequate birth-control measures (e.g. intrauterine device, diaphragm or condom [for male partner] with spermicidal jelly or foam, or birth control pills/patches) throughout the course of the study

• Subject has participated in another clinical study and has been exposed to an investigational product (IP) or device within 30 days prior to study enrollment (exception: treatment with immunoglobulin pre-study)

• Subject is scheduled to participate in another (non-Baxter) non-observational (interventional) clinical study involving an IP or device during the course of the study

• Subject has severe dermatitis that would preclude adequate sites for safe product administration

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Primary Immunodeficiency Diseases (PID)

Intervention

Biological:
• Immune Globulin Subcutaneous (Human), 20%
Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
• Immune Globulin Intravenous (Human), 10%
Intravenous infusion (regulated via a pump)
• Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
Subcutaneous infusion (regulated via a pump)

Locations

Country	Name	City	State
Austria	Medizinische Universität Wien / AHK Wien (General Hospital Vienna), Universitätsklinik für Kinder- und Jugendheilkunde	Vienna
Germany	Universitätsklinikum Erlangen, Medizinische Klinik 3	Erlangen
Germany	University Medical Centre Freiburg, Centre of Chronic Immunodeficiency, Divison of Rheumatology and Clinical Immunology	Freiburg
Germany	Universitätsklinikum Hamburg-Eppendorf, Kinderklinik	Hamburg
Germany	Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie	Hannover
Germany	Klinikum St. Georg GmbH, Klinik für Kinder- und Jugendmedizin	Leipzig
Hungary	Fovárosi Önkormányzat Egyesített Szent István és Szent László Kórház, Gyermekhematológiai és Ossejt-transzplantációs Osztály	Budapest
Hungary	University of Debrecen, Medical and Health Science Center, Department of Infectious and Pediatric Immunology	Debrecen
Sweden	The Queen Silvia Children´s Hospital	Gothenburg
United Kingdom	Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Immunology Department	Birmingham
United Kingdom	Addenbrooke´s Hospital, Department of Clinical Immunology	Cambridge
United Kingdom	Royal London Hospital, Barts and the London NHS Trust, Department of Immunology	London

Sponsors (1)

Lead Sponsor	Collaborator
Baxalta now part of Shire

Countries where clinical trial is conducted

Austria,  Germany,  Hungary,  Sweden,  United Kingdom, 

References & Publications (1)

Borte M, Kriván G, Derfalvi B, Maródi L, Harrer T, Jolles S, Bourgeois C, Engl W, Leibl H, McCoy B, Gelmont D, Yel L. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in pa — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acute serious bacterial infection rate defined as the mean number of acute serious bacterial infections per subject per year in the intent-to-treat population	Acute serious bacterial infections will include bacteremia / sepsis, bacterial meningitis, osteomyelitis / septic arthritis, bacterial pneumonia, and visceral abscess, diagnosed according to the Diagnostic Criteria for Serious Acute Bacterial Infections	1 year